Skip to main content

Research Repository

Advanced Search

Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility)

Higginson, Irene J.; Wilcock, Andrew; Johnson, Miriam J.; Bajwah, Sabrina; Lovell, Natasha; Yi, Deokhee; Hart, Simon P.; Crosby, Vincent; Poad, Heather; Currow, D.C.; Best, Emma; Brown, S.R.

Authors

Irene J. Higginson

Miriam J. Johnson

Sabrina Bajwah

Natasha Lovell

Deokhee Yi

Simon P. Hart

Vincent Crosby

Heather Poad

D.C. Currow

Emma Best

S.R. Brown



Abstract

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. New treatments are required for severe breathlessness in advanced disease. We conducted a randomised feasibility trial of mirtazapine over 28 days in adults with a modified medical research council breathlessness scale score ≥3. Sixty-four patients were randomised (409 screened), achieving our primary feasibility endpoint of recruitment. Most patients had COPD or interstitial lung disease; 52 (81%) completed the trial. There were no differences between placebo and mirtazapine in tolerability or safety, and blinding was maintained. Worst breathlessness ratings at day 28 (primary clinical activity endpoint) were, 7.1 (SD 2.3, placebo) and 6.3 (SD 1.8, mirtazapine). A phase III trial of mirtazapine is indicated. Trial registration: ISRCTN 32236160; European Clinical Trials Database (EudraCT no: 2015-004064-11).

Citation

Higginson, I. J., Wilcock, A., Johnson, M. J., Bajwah, S., Lovell, N., Yi, D., …Brown, S. (2020). Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility). Thorax, 75(2), 176-179. https://doi.org/10.1136/thoraxjnl-2019-213879

Journal Article Type Article
Acceptance Date Nov 18, 2019
Online Publication Date Jan 8, 2020
Publication Date 2020-02
Deposit Date Nov 29, 2019
Publicly Available Date Nov 29, 2019
Journal Thorax
Print ISSN 0040-6376
Electronic ISSN 1468-3296
Publisher BMJ Publishing Group
Peer Reviewed Peer Reviewed
Volume 75
Issue 2
Pages 176-179
DOI https://doi.org/10.1136/thoraxjnl-2019-213879
Keywords COPD Exacerbations; Emphysema; Lung Cancer; Palliative Care; Psychology; COPD Pharmacology; Drug reactions; Idiopathic pulmonary fibrosis
Public URL https://nottingham-repository.worktribe.com/output/3443583
Related Public URLs https://thorax.bmj.com/
Additional Information Authors on behalf of BETTER-B Feasibility Trial Group.

Files

Randomised, double-blind, mult-centre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B Feasibility) (951 Kb)
PDF

Publisher Licence URL
http://creativecommons.org/licenses/by-nc/4.0/





You might also like



Downloadable Citations